

Assoc. Prof. Abdullah Sakin

Personal Information

Email: abdullahsakin@yyu.edu.tr

Web: <https://avesis.yyu.edu.tr/abdullahsakin>

International Researcher IDs

ORCID: 0000-0003-2538-8569

Yoksis Researcher ID: 286704

Education Information

Post Doctorate of Medicine, University Of Health Sciences, Okmeydanı Eğitim Ve Araştırma Hastanesi, Tıbbi Onkoloji, Turkey 2015 - 2018

Expertise In Medicine, Diğer (Kurumlar,hastaneler Vb.), Turkey 2015 - 2018

Expertise In Medicine, University Of Health Sciences, Haseki Eğitim Ve Araştırma Hastanesi, İç Hastalıkları, Turkey 2008 - 2012

Undergraduate, Bursa Uludağ University, Elektronik Ve Haberleşme Mühendisliği, Turkey 2001 - 2007

Foreign Languages

English, B1 Intermediate

Dissertations

Expertise In Medicine, Periton Diyalizi Hastalarında Plazma Stweak(TNF-Like Weak Inducer Of Apoptosis) Düzeyi İle Kardiyak Hastalıklar Arasındaki İlişki, Diğer (Kurumlar,hastaneler Vb.), 2012

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

Academic Titles / Tasks

Assistant Professor, Van Yüzüncü Yil University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2019 - Continues

Academic and Administrative Experience

Head of Department, Van Yüzüncü Yil University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2019 - 2020

Advising Theses

Sakin A., Neoadjuvan tedavi verilen lokal ileri meme kanseri hastalarında tedavi yanıtını etkileyen faktörler, Postgraduate, C.Kaskalan(Student), Continues

Sakin A., Van bölgesi skuamöz hücreli özefagus kanseri tanılı hastaların demografik ve klinik verileri, Postgraduate, Y.Mamiş(Student), Continues

Sakin A., Neoadjuvan tedavi verilen mide kanseri hastalarında tedavi yanıtını etkileyen faktörler, Postgraduate, Ş.Çetin(Student), Continues

Sakin A., YUMUŞAK DOKU SARKOMU TANILI HASTALARIN KLİNİK VE DEMOGRAFİK ÖZELLİKLERİNİN DEĞERLENDİRİLMESİ; TEK MERKEZ DENEYİMİ, Expertise In Medicine, S.BUDANCAMANAK(Student), 2020

Sakin A., Opere skuamöz hücreli özofagus kanserinde sağkalımı etkileyen faktörler, Expertise In Medicine, N.AKGÜL(Student), 2020

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)**
YAŞAR H. A., Aktas B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., Sakin A., Ates O., Basoglu T., Arslan C., et al.
Clinical Genitourinary Cancer, vol.22, no.3, 2024 (SCI-Expanded)
- II. **Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC**
Yildirim M. E., Karadurmuş N., Ökten İ. N., TÜRK H. M., Uraççı Z., Arslan Ç., Çelik S., Dane F., ŞENDUR M. A. N., Bilir C., et al.
Journal of Oncology Pharmacy Practice, 2024 (SCI-Expanded)
- III. **PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study**
Avcı O., İriağaç Y., Çavdar E., Karaboyun K., Araz M., Şakalar T., Değerli E., Özdemir Ö., İnal A., Ocak B., et al.
Journal of Geriatric Oncology, vol.14, no.8, 2023 (SCI-Expanded)
- IV. **Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study**
BİLİCİ A., Koca S., Karaagac M., Aydin S. G., Eraslan E., Kaplan M. A., Ocak B., SEZGİN GÖKSU S., PAYDAŞ S., Akgül F., et al.
Journal of Cancer Research and Clinical Oncology, vol.149, no.11, pp.8243-8253, 2023 (SCI-Expanded)
- V. **Factors affecting survival in operated gastric cancer**
Sakin A., Sahin S., Sakin A., Aldemir M. N., Sakoglu N., Bayram İ., Kotan M. Ç.
Surgical Oncology, vol.46, 2023 (SCI-Expanded)
- VI. **Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study**
BAŞOĞLU TÜYLÜ T., Sakin A., Erol C., Ozden E., ÇABUK D., Cilbir E., Tataroglu ozyukseler D., Ayhan M., Sendur M. A., Dogan M., et al.
JOURNAL OF CHEMOTHERAPY, vol.35, no.2, pp.142-149, 2023 (SCI-Expanded)
- VII. **Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group**
Erol C., Nahit Sendur M. A., Bilgetekin I., Garbioglu D. B., Hamdard J., Akbas S., Hizal M., Arslan C., Sevinc A., Kucukarda A., et al.
Journal of cancer research and therapeutics, vol.18, 2022 (SCI-Expanded)
- VIII. **Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study**
Bilici A., UYSAL M., Menekse S., Akin S., Yildiz F., Turan M., SEZGİN GÖKSU S., Beypinar I., ŞAKALAR T., Degirmenci M., et al.
CANCER INVESTIGATION, vol.40, no.2, pp.199-209, 2022 (SCI-Expanded)

- IX. **Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)**
Erol C., Sakin A., BAŞOĞLU TÜYLÜ T., Ozden E., ÇABUK D., Dogan M., Oksuzoglu B., YILDIRIM H. Ç., Oner I., Eryilmaz M. K., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.4, pp.1022-1032, 2022 (SCI-Expanded)
- X. **Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer.**
Gürbüz M., Akkuş E., Sakin A., Urvay S., Demiray A., Şahin S., Şakalar T., Erol C., Şendur M., Şahin A., et al.
Tumori, vol.107, pp.416-423, 2021 (SCI-Expanded)
- XI. **Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?**
Ayhan M., Turan N., Köstek O., Tufan G., Tataroğlu Ö., Odabas H., Sakin A., Turan M., Sürmeli H., Yıldırım M.
Current problems in cancer, vol.45, 2021 (SCI-Expanded)
- XII. **Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases**
Oruc Z., Kaplan M. A., KARAAĞAÇ M., Ozyurt N., TATLI A. M., Kaya A. O., Menekse S., Kut E., Koca S., Sever O. N., et al.
FUTURE ONCOLOGY, vol.17, pp.1611-1624, 2021 (SCI-Expanded)
- XIII. **Is lymph node dissection necessary for staging while undergoing nephrectomy in patients with renal cell carcinoma?**
Demir T., Aliyev A., Beşiroğlu M., Araz M., Köstek O., Sakin A., Shbair A., Çoban G., Ersöz C., Şeker M., et al.
Current problems in cancer, vol.45, 2021 (SCI-Expanded)
- XIV. **The Effect of Body Mass Index on Treatment Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Platinum-Based Therapy**
Sakin A., Sahin S., Mustafa Atci M., Yasar N., Demir C., Geredeli C., Sakin A., Cihan S.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, vol.73, no.8, pp.1411-1418, 2021 (SCI-Expanded)
- XV. **Factors Affecting Survival in Retroperitoneal Sarcomas Treated with Upfront Surgery: A Real-World Study by Turkish Oncology Group**
Akagunduz B., AKIN TELLİ T., YILDIRIM H. Ç., SEZGİN GÖKSU S., DEMİR N., Hafizoglu E., Ozer M., Cevik G. T., Sakin A., Aydin S. G., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.31, no.2, pp.92-98, 2021 (SCI-Expanded)
- XVI. **The Prognostic Importance of Microsatellite Instability Status in Turkish Stage II and III Gastric Cancer Patients who Received Adjuvant Chemotherapy**
Arici S., Erhan S. S., Geredeli C., Atci M. M., Secmeler S., Cekin R., Sakin A., Cihan S.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.31, no.1, pp.36-42, 2021 (SCI-Expanded)
- XVII. **The Conversion of RAS Status in Metastatic Colorectal Cancer Patients After First-Line Biological Agent Treatment.**
Arici S., Hamdard J., Sakin A., Sengiz E., Mustafa A., Cekin R., Saka B., Köse E., Saydam T., Geredeli C., et al.
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, vol.23, pp.206-212, 2021 (SCI-Expanded)
- XVIII. **The effect of body mass index on location of recurrence and survival in early-stage colorectal cancer.**
Sakin A., Samanci N. S., Secmeler S., Arici S., Can O., Yasar N., Geredeli C., Demir C., Cihan S.
Journal of cancer research and therapeutics, vol.16, 2020 (SCI-Expanded)
- XIX. **The impact of tumor regression grade on long-term survival in locally advanced rectal cancer treated with preoperative chemoradiotherapy**
Sakin A., Sahin S., ŞENGÜL SAMANCI N., Yasar N., Demir C., Geredeli C., Erhan S. S., Akboru M. H., Cihan S.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.7, pp.1611-1620, 2020 (SCI-Expanded)
- XX. **Demographical and Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish Oncology Group (TOG)**
Turkkan G., Alkan A., PAYDAŞ S., Tanriverdi O., Karakas Y., Karadurmus N., Sakin A., Temiz S., Arpacı E., Akin M., et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, vol.36, no.4, pp.640-645, 2020 (SCI-Expanded)

- XXI. **Does the Waiting Period for Genetic Tests Affect the Prognosis in Chemotherapy-Treated de novo Metastatic Non-Small Cell Lung Cancer Patients without a Driver Mutation?**
Arici S, Sakin A, Cekin R, Secmeler S, Yasar N, Cihan S.
Oncology research and treatment, vol.43, pp.435-440, 2020 (SCI-Expanded)
- XXII. **Prognostic significance of basal 18F-FDG PET / CT maximum standardized uptake value in patients with metastatic renal cell carcinoma who were treated with sunitinib.**
Aytekin A., Aldemir M., Sakin A., Telci U., Esen R.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.25, pp.2490-2495, 2020 (SCI-Expanded)
- XXIII. **The Clinical Importance of Androgen Receptor Status in Response to Neoadjuvant Chemotherapy in Turkish Patients with Local and Locally Advanced Breast Cancer.**
Arici S, Sengiz E., Geredeli C., Cekin R., Sakin A., Cihan S.
Oncology research and treatment, vol.43, pp.435-440, 2020 (SCI-Expanded)
- XXIV. **The predictive role of metabolic tumor volume on no response to neoadjuvant chemotherapy in patients with breast cancer.**
ARICI S., Karyagar S., Karyagar S., GEREDELI C., CEKIN R., SECMELER S., ATCI M., Sakin A., CIHAN S.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, vol.26, no.6, pp.1415-1420, 2020 (SCI-Expanded)
- XXV. **The Effect of Obesity on Response to Neoadjuvant Therapy in Locally Advanced Gastric Cancer.**
Sakin A., Sahin S., Sakin A., Aldemir M., Bayram I., Kotan C.
Asian Pacific journal of cancer prevention : APJCP, vol.21, pp.2723-2731, 2020 (SCI-Expanded)
- XXVI. **Assessment of pretreatment albumin-bilirubin grade in pancreatic cancer patients with liver metastasis.**
Sakin A., Sahin S., Sakin A., Atci M., Yasar N., Arici S., Geredeli C., Karatas F., Cihan S.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.25, pp.1941-1946, 2020 (SCI-Expanded)
- XXVII. **The prognostic significance of the 18F-fluorodeoxyglucose positron emission tomography/computed tomography in early-stage nonsmall cell lung cancer.**
Geredeli C., Artac M., Kocak I., Koral L., Sakin A., Altinok T., Kaya B., Karaagac M.
Journal of cancer research and therapeutics, vol.16, pp.816-821, 2020 (SCI-Expanded)
- XXVIII. **Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?**
Bozkaya Y., Kostek O., Sakin A., Ozyukseler D. T., Sakalar T., Cil I.
SUPPORTIVE CARE IN CANCER, vol.28, no.5, pp.2273-2282, 2020 (SCI-Expanded)
- XXIX. **The effects of diabetes and fasting plasma glucose on treatment of breast cancer with neoadjuvant chemotherapy.**
ARICI S., GEREDELI C., SECMELER S., CEKIN R., Sakin A., CIHAN S.
Current problems in cancer, vol.44, pp.100485, 2020 (SCI-Expanded)
- XXX. **Clinical outcomes of patients with pure small cell carcinoma of the urinary bladder**
Erdem G. U., Doğan M., Aytekin A., Sahin S., Cinkir H. Y., Sakin A., Ozcelik M., Bozkurt O., Sezer E., Demirci N. S., et al.
Irish Journal Of Medical Science, pp.431-438, 2020 (SCI-Expanded)
- XXXI. **Adrenocortical Carcinoma:Single Center Experience**
Sakin A., Secmeler S., Can O., Arici S., Geredeli C., Yasar N., Demir C., Sakin A., Cihan S.
Archives Of Medical Research, pp.52-56, 2020 (SCI-Expanded)
- XXXII. **Mean platelet volume and platelet distribution width correlates with prognosis of early colon cancer**
Sakin A., Sahin S., Sakin A., KARATAŞ F., Samanci N. S., Yasar N., Arici S., Demir C., Geredeli C., Dikker O., et al.
JOURNAL OF BUON, vol.25, no.1, pp.227-239, 2020 (SCI-Expanded)
- XXXIII. **The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer.**
Sakin A., SAHIN S., ATCI M., SAKIN A., YASAR N., GEREDELI C., AKSARAY F., CIHAN S.
PULMONOLOGY, no.19, pp.30215-30216, 2019 (SCI-Expanded)
- XXXIV. **Systemic Inflammatory Markers as a Predictors of Response to Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer**

- Bilici A, Olmez O. F., GÜRSOY P., Cubukcu E., Yildiz O., Sakin A., KORKMAZ T., CIL I., ÇAKAR B., MENEKSE S., et al.
JOURNAL OF THORACIC ONCOLOGY, vol.14, no.10, 2019 (SCI-Expanded)
- XXXV. **The Relation between Hemogram Parameters and Survival in Extensive-Stage Small Cell Lung Cancer**
Sakin A., Sahin S., Yasar N., Demir C., Arıcı S., Geredeli C., Cihan S.
ONCOLOGY RESEARCH AND TREATMENT, vol.42, pp.506-514, 2019 (SCI-Expanded)
- XXXVI. **Factors affecting survival and treatment efficacy in breast cancer patients with bone marrow metastasis**
Sakin A., Sakalar T., Sahin S., Yasar N., Demir C., Geredeli C., Cihan S.
BREAST JOURNAL, 2019 (SCI-Expanded)
- XXXVII. **Factors affecting survival in patients with isolated liver-metastatic colorectal cancer treated with local ablative or surgical treatments for liver metastasis.**
Sakin A., Sahin S., Atci M., Yasar N., Geredeli C., Aribal S., Alemdar A., Karataş F., Cihan S.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.24, pp.1801-1808, 2019 (SCI-Expanded)
- XXXVIII. **Factors Affecting Disease-Free Survival in Operated Nonmetastatic Gastrointestinal Stromal Tumors**
Sakin A., Can O., Arici S., Yasar N., Geredeli C., Demir C., Cihan S.
JOURNAL OF SURGICAL RESEARCH, vol.241, pp.170-177, 2019 (SCI-Expanded)
- XXXIX. **Efficacy and tolerability of adjuvant therapy in ≥ 70 -year-old patients with T3N0M0 colorectal cancer: An observational study**
Sakin A., YASAR N., SAHIN S., ARICI S., SECMELELER S., CAN O., GEREDELI C., DEMIR C., CIHAN S.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019 (SCI-Expanded)
- XL. **Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy**
Sakin A., SAHIN S., YASAR N., DEMIR C., ARICI S., GEREDELI C., CIHAN S.
LUNG CANCER, vol.133, pp.38-44, 2019 (SCI-Expanded)
- XLI. **Effect of Pretreatment Platelet Parameters on Survival in Limited Disease Small Cell Lung Cancer.**
Sakin A., YASAR N., ARICI S., DEMIR C., GEREDELI C., AKSARAY F., ISIK S., CIHAN S.
Asian Pacific journal of cancer prevention : APJCP, vol.20, pp.1879-1885, 2019 (SCI-Expanded)
- XLII. **The efficacy and reliability of sequential adjuvant anthracycline-based chemotherapy and weekly paclitaxel regimen in human epidermal growth factor receptor 2 negative breast cancer: A retrospective analysis of a multicentre study.**
Ali K., ORUC Z., GUMUS M., OZAYDIN S., ELKIRAN E., DINC N., Sakin A., BERK V., AKMAN T., AYTEKIN A., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.24, pp.1081-1086, 2019 (SCI-Expanded)
- XLIII. **Prognostic Significance of Mean Platelet Volume on Local Advanced Non-Small Cell Lung Cancer Managed with Chemoradiotherapy.**
Sakin A., Secmeler S., Arıcı S., Geredeli C., Yasar N., Demir C., Aksaray F., Cihan S.
Scientific reports, vol.9, pp.3959, 2019 (SCI-Expanded)
- XLIV. **Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?**
KÖSTEK O., HACIOĞLU M., Sakin A., DEMİR T., SARİ M., OZKUL O., ARAZ M., DOĞAN A., DEMİRCAN N., UZUNOĞLU S., et al.
Cancer chemotherapy and pharmacology, vol.83, pp.115-122, 2019 (SCI-Expanded)
- XLV. **A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).**
DEGIRMENCIOĞLU S., TANRIVERDİ O., MENEKSE S., DOĞAN M., HACIOĞLU B., OKTAY E., ERDEM D., ARPACI E., ULUC B., TURHAL S., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.24, pp.136-142, 2019 (SCI-Expanded)
- XLVI. **Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent, Young Adults, and Adults) of Colorectal Cancer Patients: A Multicentre Study.**
Kaplan M., Ozaydin S., Yerlikaya H., Karaagac M., Gumus M., Cil T., Yalcintas A., Ozdemir N., Sakin A., Bilici M., et al.
Oncology research and treatment, vol.42, pp.516-522, 2019 (SCI-Expanded)

- XLVII. **Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.**
Esin E., Oksuzoglu B., Bilici A., Cıcm I., Köstek O., Kaplan M., Aksoy S., Aktas B., Ozdemir O., Alacacioglu A., et al.
Cancer chemotherapy and pharmacology, vol.83, pp.131-143, 2019 (SCI-Expanded)
- XLVIII. **A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)**
Degirmencioglu S., Tanriverdi O., Menekse S., Dogan M., Hacıoglu B., Oktay E., Erdem D., Arpacı E., Uluc B. O., Turhal S., et al.
JOURNAL OF BUON, vol.24, no.1, pp.242-248, 2019 (SCI-Expanded)
- XLIX. **Factors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience**
Sakin A., Tambas M., Secmeler S., Can O., Arıcı S., Yasar N., Geredeli C., Demir C., Cihan S.
Asian Pacific journal of cancer prevention : APJCP, vol.19, pp.3597-3603, 2018 (SCI-Expanded)
- L. **Prognostic significance of primary tumor localization in stage II and III colon cancer.**
Sakin A., Arıcı S., Secmeler S., Can O., Geredeli C., Yasar N., Demir C., Demir O., Cihan S.
World journal of gastrointestinal oncology, vol.10, pp.410-420, 2018 (SCI-Expanded)
- LI. **Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder.**
Erdem G., Dogan M., Sakin A., Oruc Z., Yaman E., Yesil C., Uysal M., Bozkurt O., Ozturk B., Aytekn A., et al.
Oncology research and treatment, vol.41, pp.220-225, 2018 (SCI-Expanded)
- LII. **Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients.**
Toprak Z., Cebeci E., Helvacı S., Toprak I., Kutlu Y., Sakin A., Tupek T.
International urology and nephrology, vol.49, pp.1041-1047, 2017 (SCI-Expanded)
- LIII. **Evaluation of Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 Expression Levels in Patients with Chronic Lymphocytic Leukemia.**
Ayer M., Sakin A., Ay S., Ayer A., Sazak E., Aktan M.
Turkish journal of haematology : official journal of Turkish Society of Haematology, vol.33, pp.335-338, 2016 (SCI-Expanded)
- LIV. **THE RELATIONSHIP BETWEEN SOLUBLE TUMOR NECROSIS FACTOR-LIKE WEAK INDUCER OF APOPTOSIS LEVELS AND CARDIAC FUNCTIONS IN PERITONEAL DIALYSIS PATIENTS**
Karadag S., Gursu M., Sakin A., Atalay E., Basinoglu F., Aydın Z., Uzun S., Sumnu A., Cebeci E., Koldas M., et al.
EUROPEAN JOURNAL OF INFLAMMATION, vol.12, pp.429-437, 2014 (SCI-Expanded)
- LV. **Spontaneous renal cholesterol crystal embolism in a patient with functionally solitary kidney Tek böbrekli bir hastada spontan renal kolesterol kristal embolisi**
Celik K., Sumnu A., Gursu M., Sakin A., Uzun S., Ozturk S., KAZANCIOĞLU R.
European Journal of General Medicine, vol.11, no.2, pp.126-129, 2014 (SCI-Expanded)
- LVI. **Reversible sensorineural hearing loss in celiac disease: Is it a coincidental finding? Çölyak hastalığı{dotless}nda geçici sensorinöral işitme kaybı{dotless}: Rastlantı{dotless}sal bir bulgu mu?**
ÇELİK K., Sakin A., ÖZTÜRK S., Yılmaz M., YIGİT N., FEYİZOĞLU H., GÜRBÜZEL M.
Haseki Tıp Bulteni, vol.51, no.4, pp.190-192, 2013 (SCI-Expanded)
- LVII. **A case of necrotizing lymphadenitis; Kikuchi Fujimoto disease Nekrotizan lenfadenopati olgusu; Kikuchi-Fujimoto hastalığı**
Sakin A., Ayer M., Sakin A., Çelik K., Tosyalı Y.
Haseki Tıp Bulteni, vol.50, pp.142-145, 2012 (SCI-Expanded)

Articles Published in Other Journals

- I. **The Predictive Value of Baseline Volumetric PET/CT Parameters on Treatment Response and**

Prognosis in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy

Sakin A., Sahin S., Karyagar S. S., Karyagar S., Atci M., Akboru M. H., Cihan S.

JOURNAL OF GASTROINTESTINAL CANCER, vol.53, no.2, pp.341-347, 2022 (ESCI)

- II. **Factors Affecting Survival in Operated Esophageal Squamous Cell Carcinoma**
Akgül N., Sakin A., Sahin S., Aldemir M. N., Aytakin A., Alay M., Ilklerden Ü. H., Kotan M. C.
JOURNAL OF GASTROINTESTINAL CANCER, vol.53, no.2, pp.439-445, 2022 (ESCI)
- III. **Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group**
Gurbuz M., Akkus E., Sakin A., Urvay S., Demiray A. G., Sahin S., Sakalar T., EROL C., ŞENDUR M. A. N., ŞAHİN A. B., et al.
JOURNAL OF GASTROINTESTINAL CANCER, vol.53, no.2, pp.282-288, 2022 (ESCI)
- IV. **The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study**
Beypinar I., Demir H., Sakin A., Taskoylu B. Y., Sakalar T., Ergun Y., Korkmaz M., Ates O., Eren T., Turhal S., et al.
JOURNAL OF GASTROINTESTINAL CANCER, vol.52, no.3, pp.932-939, 2021 (ESCI)
- V. **Prognostic significance of neutrophil-to-lymphocyte ratio in esophageal squamous cell carcinoma**
Sakin A., Alay M., Sahin S., Aydemir O., Aldemir M. N., Sakin A., Kotan C.
NORTHERN CLINICS OF ISTANBUL, vol.8, no.5, pp.435-442, 2021 (ESCI)
- VI. **The clinical importance of fibroblast growth factor 23 on advanced non-small cell lung cancer patients without druggable alterations in genes as EGFR or ALK or ROS1 Fibroblast growth factor 23**
Arıcı S., Çekin R., Seçmeler Ş., Atçı M. M., Ocak B., Sakin A., Cihan Ş.
Eurasian Journal of Medical Investigation, vol.4, no.3, pp.365-369, 2020 (Peer-Reviewed Journal)
- VII. **Red Blood Cell Distribution Width as a Possible Predictor of Diagnosis and Survival in Gastric Cancer**
Sakin A., Aydemir O., Şahin S., Alay M., Aytakin A., Aldemir M. N., Kotan M. Ç., Esen R., Sakin A.
Eurasian Journal of Medical Investigation, vol.4, no.3, pp.289-297, 2020 (Peer-Reviewed Journal)
- VIII. **C-Reactive Protein to Albumin ratio is an Indicator of Poor Prognosis for Patients with Biliary Tract Cancer.**
Demir T., Köstek O., Araz M., Sakin A., Aliyev A., Beşiroğlu M., Türk H. M.
EURASIAN JOURNAL OF MEDICINE, pp.65-70, 2020 (ESCI)
- IX. **Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience**
Sakin A., Urun Y. Y., Sahin S., Atci M. M., Arici S., Geredeli C., Yasar N., Demir C., Cihan S.
NORTHERN CLINICS OF ISTANBUL, vol.7, no.3, pp.267-274, 2020 (ESCI)
- X. **Factors affecting survival in operated pancreatic cancer: Does tumor localization have a significant effect on treatment outcomes?**
Sakin A., Sahin S., Sakin A., Atci M. M., Arici S., Yasar N., Demir C., Geredeli C., Cihan S.
NORTHERN CLINICS OF ISTANBUL, vol.7, no.5, pp.487-493, 2020 (ESCI)
- XI. **The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the second-line setting for metastatic pancreatic cancer patients with poor performance status**
Sakin A., Şahin S., Atci M. M., Demir C., Yasar N., Geredeli C., Cihan S.
TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY, pp.85-89, 2019 (Scopus)
- XII. **Non-urothelial Bladder Cancers:Single Center Experience**
Sakin A., Secmeler S., Arici S., Can O., Geredeli C., Yasar N., Demir C.
European Archives of Medical Research, pp.162-166, 2019 (Peer-Reviewed Journal)
- XIII. **Germline Mutations in BRCA1 and BRCA2 in Breast Cancer Patients with High Genetic Risk in Turkish Population.**
Geredeli C., Yasar N., Sakin A.
International journal of breast cancer, vol.2019, pp.9645147, 2019 (ESCI)
- XIV. **Effectiveness and tolerability of FOLFİRINOX regime in metastatic pancreas cancer disease**
Geredeli C., Cihan S., Yasar N., Sakin A., Can O., Artaç M., Karaağaç M., Koral L.
The Medical Journal of Okmeydani Training and Research Hospital, pp.76-81, 2018 (Peer-Reviewed Journal)
- XV. **Hereditary hyperferritinemia-cataract syndrome Herediter hiperferritinemi-katarakt sendromu**

- KUTLU O., ECIRLI Ş., Sakin A., SAĞLAM F., BAŞTÜRK A.
Nobel Medicus, vol.13, no.2, pp.80-82, 2017 (Scopus)
- XVI. **Kanserde Palyatif Tedaviler:Palyatif Kemoterapi Uygulamaları**
Sakin A., Ölmez Ö. F.
Türkiye Klinikleri Tıp Bilimleri Dergisi, pp.261-266, 2017 (Scopus)
- XVII. **Paroxysmal Nocturnal Haemoglobinuria Presenting with Acute Kidney Injury: A Case Report**
Ayer M., Sakin A., Kutlu O., Ayer A., Sakin A., Öztürk S.
The Medical Journal of Okmeydani Training an Research Hospital, pp.111-113, 2017 (Peer-Reviewed Journal)
- XVIII. **Chylothorax due to lymphadenitis of tuberculosis: Case Report**
Kutlu O., Demirbaş S., Sakin A.
NORTHERN CLINICS OF ISTANBUL, pp.225-228, 2016 (Peer-Reviewed Journal)
- XIX. **Multiple miyelomlu hastalarda polinöropati sıklığı ve laboratuvar parametrelerinin karşılaştırılması**
Sakin A., Ayer M., Çelik K., Berkil F., Acar H., Ayer A., Sakin A., Şar F.
Dicle Medical Journal /Dicle Tıp Dergisi, pp.445-448, 2016 (Peer-Reviewed Journal)
- XX. **Factors affecting survival in small cell lung cancer**
Sakin A., TURGUT E. S., Aybek M., Usta A. A., Koşan Ö., ÇELİK K., ÖZTÜRK S., Koçer M.
European Journal of General Medicine, vol.13, no.3, pp.37-41, 2016 (ESCI)
- XXI. **Kronik Tofüslü Gut: Olgu Sunumu ve Literatür Güncellemesi**
Kutlu O., Ecirli Ş., Gencer V., Sakin A., Yıldırım A.
EURASIAN JOURNAL OF FAMILY MEDICINE , pp.49-52, 2016 (Peer-Reviewed Journal)
- XXII. **Delayed Paraganglioma Diagnosis: A Case Report and Literature Update**
Ecirli S., Korkmaz M., Kutlu O., Duran C., Goren M. O., Sakin A.
ISTANBUL MEDICAL JOURNAL, vol.16, no.4, pp.162-164, 2015 (ESCI)
- XXIII. **Aggressive Natural Killer Cell Leukemia: A Case Report and Literature Update**
Ecirli S., Kutlu O., Andic N., Ugurluoglu C., Sakin A., Basturk A.
ISTANBUL MEDICAL JOURNAL, vol.16, no.3, pp.130-132, 2015 (ESCI)
- XXIV. **Tracheobronchial Amiloidosis**
Demirbas S., Kutlu O., Sakin A.
ISTANBUL MEDICAL JOURNAL, vol.16, pp.119-121, 2015 (ESCI)
- XXV. **Cerebral Amyloid Angiopathy: A Case Report and Literature Update**
Kutlu O., Ecirli S., Aygun S., Unsal I., Keskin M., Sakin A., Basturk A.
HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, vol.53, no.1, pp.92-94, 2015 (ESCI)
- XXVI. **Psödohipoparatiroidi Tip 1A: Olgu Sunumu**
Evren B., Kutlu O., Sakin A., Baştürk A., Selek Demirel F.
Fırat Tıp Dergisi, pp.165-167, 2015 (Peer-Reviewed Journal)
- XXVII. **Hereditör Pankreatit: Olgu Sunumu ve Literatür Güncellemesi**
Cavdar E., Sakin A., Arcagöz M., Fadiloğlu A., Hurşitoğlu M.
AVRASYA AİLE HEKİMLİĞİ DERGİSİ, pp.131-135, 2015 (Peer-Reviewed Journal)
- XXVIII. **Akut Koroner Sendromlu Hastalarda Majör Risk Faktörlerinin ve Laboratuvar Parametrelerinin Değerlendirilmesi**
Usta M., Sakin A., Sakin A., Çelik K., Öztürk S., Ayer A., Gürkan Y., Ulusoy M., Yiğit N., Feyizoğlu H.
Smyrna Tıp Dergisi, pp.5-11, 2015 (Peer-Reviewed Journal)
- XXIX. **Kayıp Tiroid Nerede? Lingual Tiroid**
Kutlu O., Ecirli Ş., Sakin A., Çaycı M.
Selçuk Tıp Dergisi, pp.77-78, 2015 (Peer-Reviewed Journal)
- XXX. **Amenore ile Seyreden De Morsier Sendromu**
Kutlu O., Şahin I., Sakin A., Evren B.
Fırat Tıp Dergisi, pp.60-62, 2015 (Peer-Reviewed Journal)
- XXXI. **A rare cause of pleural effusion: adult onset Still's disease**
Demirbas S., Kutlu O., Kandemir B., Sakin A.
NORTHERN CLINICS OF ISTANBUL, vol.2, no.2, pp.155-158, 2015 (ESCI)

- XXXII. **Rhabdomyolysis Developed Due to Hypothyroidism: Two Case Reports**
Sakin A., Çelik K., Sakin A., Öztürk S.
JOURNAL OF ACADEMIC EMERGENCY MEDICINE CASE REPORTS, pp.63-65, 2014 (Peer-Reviewed Journal)
- XXXIII. **Kalp Yetmezliğinin Tanısında ve Tedavi Sonrası Takibinde Brain Natriüretik Peptidin Önemi ve Karvedilol Tedavisinin Etkinliği**
Kimyon G., Sakin A., Yiğit N., Sakin A., Gürkan Y., Ayer A., Ulusoy M., Aktuğlu M. B., Feyizoğlu H.
Smyrna Tıp Dergisi, pp.13-18, 2014 (Peer-Reviewed Journal)
- XXXIV. **Postmenapozal Kadınlardan Hipertansif Olanlar ile Normotansif Olanlar Arasındaki Kemik Mineral Yoğunluğu**
Sakin A., Güner S., Çelik K., Sakin A., Htway Z., Feyizoğlu H., Öztürk S.
Smyrna Tıp Dergisi, pp.13-17, 2013 (Peer-Reviewed Journal)
- XXXV. **Retroperitoneal Fibroz: Olgu Sunumu ve Literatür Güncellemesi**
Çelik K., Sakin A., Öztürk S., Yiğit N., Feyizoğlu H.
Haseki Tıp Dergisi, pp.72-75, 2012 (Peer-Reviewed Journal)
- XXXVI. **Bruselloza Bağlı Bir Febril Nötropeni Olgusu**
Sakin A., Çelik K., Öztürk S., Sakin A., Yiğit N., Feyizoğlu H., Ayer M.
Haseki Tıp Bülteni, pp.69-71, 2012 (Scopus)

Books & Book Chapters

- I. **Triple Negatif Meme Kanseri**
Sakin A.
in: KLİNİK ÇALIŞMALARLA ONKOLOJİDE HEDEFLİ TEDAVİLER, Cihan Ş.Geredeli Ç, Demir C., Editor, Hipertup, İstanbul, pp.93-97, 2019
- II. **Üst Gastrointestinal Sistem Tümörleri**
Sakin A.
in: KLİNİK ÇALIŞMALARLA ONKOLOJİDE HEDEFLİ TEDAVİLER, Cihan Ş.Geredeli Ç, Demir C., Editor, Hipertup, İstanbul, pp.23-31, 2019
- III. **Kemoterapinin genel prensipleri**
Sakin A., Keskin S.
in: Üroonkoloji kitabı, Özen H,Türkeri L,Bedük Y,Çağ Ç, Editor, Pelin Ofset Matbaacılık, Ankara, pp.163-175, 2017

Refereed Congress / Symposium Publications in Proceedings

- I. **Are Pretreatment Inflammation-Based Prognostic Scores Useful in Predicting the Outcomes of Patients with ALK-Positive NSCLC?**
Ölmez Ö. F., Bilici A., Gürsoy P., Çubukçu E., Yıldız O., Sakin A., Korkmaz T., Çakar B., Menekşe S., Açıkgöz O.
World Conference of Lung Cancer: Conquering Thoracic Cancers Worldwide, Barcelona, Spain, 07 September 2019, pp.551-552
- II. **Metastatik Pankreas Kanseri 2. Basamak Tedavide Kombinasyon Tedavisi Alamayan Hastalarda Tek Ajan Gemsitabin ve Kapesitabin Etkinliğinin Karşılaştırılması**
Sakin A., Yasar N.
23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019, no.5803910, pp.196
- III. **Renal hücreli karsinom tanılı hastalarda nefrektomi esnasında lenf nodu disseksiyonu gerekli midir?**
Demir T., Araz M., Köstek O., Sakin A., Shbair A. T. M., Aliyev A., Çoban E., Beşiroğlu M., Şeker M., Türk H. M.
23. Ulusal kanser kongresi, Antalya, Turkey, 17 - 21 April 2019, no.5355012, pp.187-188
- IV. **Opere mide kanserli hastalarda Albumin/Globulin oranının Prpgnoz ile ilişkisi**
Sakin A.
Gastrointestinal sistem onkoloji sempozyumu, Muğla, Turkey, 21 - 23 March 2019, no.5348387, pp.13-14

- V. Sakin A., Arici S.
2. Gençlerle onkolojiye bakış kongresi, Antalya, Turkey, 14 - 17 February 2019, no.5354971
- VI. **Treatment options in patients with metastatic pancreatic cancer older 70 years best supportive care, single agent chemotherapy and combination chemotherapy**
Sakin A., Arici S.
8. İnternational gastrointestinal cancer conference , İstanbul, Turkey, 7 - 09 December 2018
- VII. **Metastatik Kolorektal Kanser Tedavisinde 3.Basamak:Yeniden Kemoterapi Vs.Regorafenib**
Köstek O., Hacıoğlu M. B., Sakin A., Demir T., Sarı M., Özkul Ö., Araz M., Demircan N. C.
2.Ulusal immünoterapi ve onkoloji kongresi, Antalya, Turkey, 31 October - 04 November 2018, no.5803954
- VIII. **The Relationship Between Pathological Complete Response and Ki 67 İndex in Patients with Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy: Retrospective Single Center Experience**
Geredeli C., Arici S., Sakin A., Yasar N., Cihan S.
2. Ulusal İmmünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018, no.5534083
- IX. **Metastatik mide kanserinde tanı anındaki PET-CT SUV-Max değerinin prognostik önemi**
Sakin A., Geredeli C.
2. Ulusal immünoterapi ve onkoloji kongresi, Antalya, Turkey, 31 October - 04 November 2018, no.5210009
- X. **Metastatik Meme Kanserinde Ne Durumdayız?**
Özyükseller Tataroğlu D., Başak M., Sakin A., Yıldırım E.
2. Ulusal immunoterapi ve onkoloji kongresi, Antalya, Turkey, 31 October - 04 November 2018, no.5534119
- XI. **Metastatik Kolorektal Kanser Tedavisinde 3.Basamak: Yeniden Kemoterapi Vs Regorafenib**
Köstek O., Hacıoğlu M. B., Sakin A., Demir T., Sarı M., Özkul Ö., Araz M., Demircan N. C.
2. ULUSAL İMMÜNÖTERAPİ VE ONKOLOJİ KONGRESİ, Antalya, Turkey, 31 October - 04 November 2018, no.6104155
- XII. **The Efficacy an Safety of Crizotinib in Patients With ROS1 Positive Advanced Stage NSCLC:The Real-world Experince from Turkey**
Kılıçkap S., Ölmez Ö. F., Çiçin İ., Demirci U., Alan Ö., Çabuk D., Şakalar T., Tath A. M., Buğdaycı Başol F., Eralp Y., et al.
European Society for Medical Onkology 2018 Congress, Munich, Germany, 19 - 23 October 2018
- XIII. **Kemoradyoterapi tedavisi verilen Sınırlı evre Küçük hücreli Akciğer Kanserinde Tümör lokalizasyonun sağkalıma etkisi**
Sakin A., Secmeler S.
5. Karadeniz Onkoloji Günleri, Trabzon, Turkey, 28 - 30 September 2018, no.5348186
- XIV. **Crizotinib Efficacy in ALK-positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experince from Turkey**
Kılıçkap S., Öztürk A., Karadurmuş N., Korkmaz T., Yumuk Perran F., Çiçin İ., Paydaş S., Çilbir E., Şakalar T., Uysal M., et al.
IASLC 19th World Conference on Lung Cancer 20181, Toronto, Canada, 23 - 26 September 2018, no.6098908
- XV. **Opere iyi diferansiye Gastroenteropankreatik nöroendokrin tümörlerde Lenf nodu tutulumunun ve primer tümör lokalizasyonunun Klinik önemi**
Sakin A., Can O., Arici S., Secmeler S., Yasar N., Geredeli C., Demir C., Cihan S.
Sağlık Bilimleri Üniversitesi İç Hastalıkları Kongresi, İstanbul, Turkey, 27 - 30 June 2018, no.5348466
- XVI. **Pleomorfik Sarkom tanılı hastada ifosfamid toksisitesi**
Secmeler S., Yasar N., Geredeli C., Demir C., Can O., Sakin A., Arici S., Cihan S.
7. Tıbbi onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, no.5355057
- XVII. **Nüks Apendiks Adenokarsinoid Tümörü:Olgu Sunumu ve Literatür Güncellemesi**
Sakin A., Yasar N., Geredeli C., Demir C., Can O., Secmeler S., Arici S., Erhan S. Ş., Cihan S.
7. tıbbi onkoloji kongresi, Antalya, Turkey, 21 - 25 March 2018, no.5355085
- XVIII. **Erken evre(1-3) kolon kanseri hastalarında tümör lokalizasyonunun hastalığı sağkalım ve genel sağkalıma etkisi:tek merkez deneyimi**
Sakin A., Yasar N., Geredeli C., Demir C., Can O., Secmeler S., Arici S., Cihan S.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, no.5803971

- XIX. Hormon pozitif metastatik meme kanseri tedavisinde Fulvestrant etkinlik ve tolerabilitesi**
Geredeli C., Cihan S., Yasar N., Demir C., Sakin A., Can O.
. Tıbbi onkoloji kongresi, Antalya, Turkey, 21 - 25 March 2018, no.5354942
- XX. Türkiye'de Metastatik Meme Kanserinde HER-2 Hedefli Tedavide Pertuzumab Kullanımının Erken Dönem Güvenlik Verileri**
Ece E., Çakmak Öksüzoğlu Ö. B., Sakin A., Çabuk D., Yıldırım N., Karaağaç M., Olgun P., Şakalar T., Aktaş B. Y., Değirmencioglu S., et al.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018
- XXI. Opere erken evre kolon kanserinde vücut kitle indeksinin nüks lokalizasyonu, hastalısız sağkalım ve genel sağkalım etkisi**
Sakin A., Yasar N., Can O., Geredeli C., Demir C., Secmeler S., Arici S., Cihan S.
Gençlerle onkolojiye bakış, Antalya, Turkey, 15 - 18 February 2018, no.5803890
- XXII. Metastatik Pankreas Kanseri Türk Hastalarda FOLFİRINOX Rejiminin Etkinlik ve Tolerabilitesi**
Geredeli Ç., Sakin A., Yaşar N., Şener C., Can O., Karaağaç M., Koral L., Artaç M.
XII. Klinik Onkolojide Güncel Tedaviler Sempozyumu-Medikal Onkoloji Günleri , İzmir, Turkey, 19 - 21 May 2017, no.6098670
- XXIII. Marjinal Zon Lenfomalarının Demografik ve Klinik Özellikleri:Türk Onkoloji Grubu Retrospektif Çalışması**
Tanrıverdi Ö., Paydaş S., Karakaş Y., Karadurmuş N., Sakin A., Temiz S., Arpacı E., Akın M., Menekşe S., Şen C. A., et al.
22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017, no.6081967, pp.323
- XXIV. kras wild tip metastatik kolorektal kanser Birinci sıra tedavide Bevasizumab,setuksimab ve panitumumab içeren rejimlerin etkinlik ve yan etki profilinin retrospektif değerlendirilmesi(türk onkoloji grubuna ait option çalışmasının ilk sonuçları)**
Tanrıverdi Ö., Hacıoğlu M. B., Menekşe S., Doğan M., Değirmencioglu S., Oktay E., Erdem D., Arpacı E., Oyan Uluç B., Turhal S., et al.
22. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 19 - 23 April 2017, no.5300387, pp.241
- XXV. Efficacy and tolerability of first-line chemotherapy in elderly patients (age \geq 70 years) with metastatic gastric cancer: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)**
ALDEMİR M. N., Turkeli M., Hacıoğlu B., SAKIN A., Yaman E., Coban E., KOCA D., Karaca M., Simsek M., Bahceci A., et al.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 7 - 11 October 2016, vol.27
- XXVI. EXTENSİVENESS OF DİSEASE,PERFORMANCE SCORE AND EFFECT OF CHEMOTHERAPY ON SURVIVAL IN PATİENTS WITH SMALL CELL LUNG CANCER**
Turgut E. S., Koçer M., Ayberk M., Sakin A., Usta A. A.
16. World Conference on Lung Cancer , Colorado, United States Of America, 6 - 09 September 2015, no.5534032
- XXVII. INVESTİGATION OF THE NUMBER OF ABSOLUTELYMPHOCYTES AS A RISK FACTOR OF HODGKIN AND NON-HODGKIN LENFOMIA**
Ayer M., Sakin A., Ayer A., Ahmedyar N., Gursu M., Sakin A., Öztürk S., Kumbasar A.
5th International Congress on Leukemia-Lymphoma-Myeloma, İstanbul, Turkey, 21 - 23 May 2015, no.5355179
- XXVIII. Üst gastrointestinal kanama ile başvuran aortoenterik fistül**
Irak K., Sakin A., Fikri İleri B.
14. Çapa gastroenteroloji günleri, İstanbul, Turkey, 9 - 11 April 2015, no.5355131
- XXIX. Toksik hepatitli graves hastasında metimazole bağlı toksik hepatit olgu sunumu**
Kutlu O., Ecirli Ş., Can M., Keskin M., Sakin A.
31. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 25 - 30 November 2014, no.5355205
- XXX. Akut Dopamin Eksikliği Sendromu:Olgu Sunumu**
Renkliyildiz B., Kutlu O., Ecirli Ş., Sakin A.
16. Uulusal iç hastalıkları kongresi, Antalya, Turkey, 15 - 19 October 2014, no.5355221

Metrics

Publication: 126

Citation (WoS): 51

Citation (Scopus): 68

H-Index (WoS): 4

H-Index (Scopus): 4